NeOnc Executives Buy Shares Following Positive Clinical Results
News related to:NeOnc Technologies Holdings · 2 min read
DENVER, Sept. 16, 2026 /CourierPR/ -- NeOnc Technologies Holdings, a biotech firm developing treatments for central nervous system cancers, has seen its stock gain renewed attention following positive Phase 2a results for its experimental brain-cancer therapy NEO100. The company’s executives have been actively buying shares of their own stock, signaling their confidence in the company’s future.
CEO Amir F. Heshmatpour and Chief Medical Officer and Chief Scientific Officer Thomas C. Chen, MD, PhD, have collectively spent approximately $629,000 on NeOnc shares since the company announced its Phase 2a results on August 12. Heshmatpour purchased 35,000 shares on September 15 for about $115,400, bringing his total post-results purchases to 111,000 shares valued at approximately $418,700. This brings his personal investment in NeOnc to over $1.5 million over the past year.
Chen, on the other hand, purchased 49,016 shares for around $210,000. Combined, the two executives have now bought 160,016 shares, a significant investment that underscores their belief in the company’s potential.
The positive Phase 2a results for NEO100 are particularly noteworthy. The therapy met its primary endpoint, achieving a six-month progression-free survival rate of 48.9%, compared to a pre-specified 20% benchmark for standard of care. The company reported a p-value of 0.0047 and a median overall survival of 26.09 months. These results are a significant milestone for NeOnc, as they highlight the potential of the NEO platform in addressing the challenges posed by the blood-brain barrier.
In addition to the positive clinical data, NeOnc has also secured additional funding through a $15 million registered direct offering. This capital will be crucial as the company advances its clinical programs, including the second program, NEO212, which has completed Phase 1 dose escalation and established a recommended Phase 2 dose.
The insider buying, combined with the positive clinical data, substantial financing, and the advancement of another clinical program, has placed NeOnc at an important inflection point.
These developments have positioned NeOnc as a company to watch, with potential for significant growth and success in the near future.